Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 5/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908257 | 1.00 | TRPA1 (0.48) | TRPA1IDO1LOXL2TAAR1LMNA | |
| SCHEMBL28253542 | 0.97 | TRPA1 (0.47) | TRPA1IDO1LOXL2TAAR1LMNA | |
| SCHEMBL17423600 | 0.93 | MAOB (0.48) | TRPA1IDO1LOXL2TAAR1LMNA | |
| SCHEMBL5563797 | 0.87 | LTA4H (0.47) | TRPA1IDO1AGXTKMT2AMAOA | |
| SCHEMBL6364651 | 0.85 | MAOB (0.40) | TRPA1LMNAKMT2AMAOB | |
| SCHEMBL22944268 | 0.84 | TRPA1 (0.41) | TRPA1IDO1LOXL2TAAR1LMNA | |
| Bromobenzene SCHEMBL27691130 | 0.83 | ALDH1A1 (0.42) | TRPA1MAOBRAB9A | |
| SCHEMBL27613782 | 0.80 | IDO1 (0.50) | TRPA1IDO1LOXL2TAAR1LMNA | |
| SCHEMBL6423021 | 0.79 | TRPA1 (0.41) | TRPA1IDO1LOXL2TAAR1LMNA | |
| SCHEMBL6423018 | 0.79 | TRPA1 (0.41) | TRPA1IDO1LOXL2TAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572761-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | claimed |
| CN-120154006-A | Application of p-fluorobenzaldehyde and composition containing p-fluorobenzaldehyde in attracting cotton bollworms | 中国农业科学院植物保护研究所 | 2025-06-17 | — | — | CN | claimed |
| CN-116113635-B | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | 辉瑞公司 | 2025-03-18 | — | — | CN | claimed |
| WO-2024038129-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | claimed |
| CN-116113635-A | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | 辉瑞公司 | 2023-05-12 | — | — | CN | claimed |
| WO-2022130403-A1 | NEW QUATERNARY AMMONIUM SALTS FOR TRIFLUOROMETHYLATION AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-06-23 | — | — | WO | claimed |
| CN-107686475-A | 2,3,5 3 substituted thiophenes, derivative and its synthetic method | 湘潭大学 | 2018-02-13 | — | — | CN | claimed |
| WO-2017013593-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LIMITED (IN) | 2017-01-26 | — | — | WO | claimed |
| CN-105461680-A | Synthetic method of 2-(4-fluorophenyl) thiophene | SUZHOU BICHAL BIOTECHNOLOGY CO LTD | 2016-04-06 | — | — | CN | claimed |
| CN-102812011-A | [1,5] -diazacyclo-octatetraene derivative | MELLITECH | 2012-12-05 | — | — | CN | claimed |
| WO-2008109336-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | claimed |
| EP-1699747-B1 | METHOD FOR THE PRODUCTION OF 2,3-CIS-SUBSTITUTED 2-ARYL PROPENALS | BASF SE (DE) | 2008-05-21 | — | — | EP | claimed |
| US-7276632-B2 | Method for the production of 2,3-cis-substituted 2-aryl propenals | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-02 | — | — | US | claimed |
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | claimed |
| US-20070093681-A1 | Method for the production of 2,3-cis-substituted 2-aryl propenals | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-26 | — | — | US | claimed |
| CN-1894189-A | Process for preparing 2, 3-cis-substituted 2-arylpropenals | BASF AG (DE) | 2007-01-10 | — | — | CN | claimed |
| EP-1699747-A2 | METHOD FOR THE PRODUCTION OF 2,3-CIS-SUBSTITUTED 2-ARYL PROPENALS | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-13 | — | — | EP | claimed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005056498-A2 | METHOD FOR THE PRODUCTION OF 2,3-CIS-SUBSTITUTED 2-ARYL PROPENALS | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-23 | — | — | WO | claimed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093681-A1 | Method for the production of 2,3-cis-substituted 2-aryl propenals | CBR3, ALDH3A1, CYP2J2 | TRPA1 1757/4885IDO1 774/4885LOXL2 341/4885 |
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | TRPA1 1987/4885IDO1 1306/4885LOXL2 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.